Press release
United States Alzheimer's Disease Therapeutics Industry Insights: Top Drugs, Pipeline and $46.47B Global Growth
Alzheimer's Therapeutics Industry
DataM Intelligence has released an in-depth research report on "Alzheimer's Disease Therapeutics Market Size 2025". This report delivers power-packed insights into key growth drivers, market segmentation, regional trends, CAGR forecasts, revenue performance of top players, and emerging opportunities. Gain a 360° market perspective with detailed analysis on value, volume, and future development trends your ultimate guide to spotting high-impact opportunities and staying ahead in this dynamic market.
Alzheimer's affects 50-60% of dementia patients. According to CSIR-NIScPR, over 57.4 million people were affected globally in 2023. The Global Burden of Disease Study projects a 166% rise in dementia cases by 2050, impacting around 152.8 million people, consistent with WHO estimates. Alzheimer's Disease International predicts dementia cases will reach 78 million by 2030 and 139 million by 2050.
The increasing global prevalence of Alzheimer's, projected to impact over 150 million people by 2050, is driving stronger demand for these therapies.
Download Your Sample PDF Today and (Get Priority Access With a Corporate Email ID For Faster Delivery):- https://datamintelligence.com/download-sample/alzheimers-disease-therapeutics-market?kb
Key Trends
High Prevalence & Aging Population: In 2025, an estimated 7.2 million Americans aged 65+ will have Alzheimer's, with 74% aged 75+. By 2050, this is projected to nearly double to 13 million, affecting 1 in 9 seniors.
Rising Healthcare Costs: Health and long-term care expenses for dementia patients are expected to reach $384 billion in 2025 and approach $1 trillion by 2050.
Supportive Market Environment: Strong pharmaceutical presence, favorable reimbursement policies, and government support for Alzheimer's research are driving North America's market growth.
Innovative Treatments: In July 2024, Eli Lilly's Kisunla (donanemab-azbt) was FDA-approved as the first amyloid plaque-targeting therapy for early symptomatic Alzheimer's, with evidence supporting treatment cessation after plaque removal.
List of Top Key Players:
Eli Lilly and Company, Pfizer Inc., Merck & Co., Inc., Eisai Co., Ltd., Merz Therapeutics, Otsuka Pharmaceutical Co., Ltd., Alpha Cognition, and Johnson & Johnson Services, Inc., among others.
Forecast Growth Projection:
Global Alzheimer's Disease Therapeutics Market Positioned for Strong Growth 2025-2032, Building on the steady momentum of 2024, the market is poised for remarkable expansion as leading players embrace innovative technologies and strategic advancements. This evolving landscape is unlocking lucrative opportunities for businesses to invest, scale, and stay ahead in an increasingly competitive and fast-moving market.
Industry Developments
In January 2025, Johnson & Johnson received FDA Fast Track designation for posdinemab, a phosphorylated tau-targeting monoclonal antibody, currently in the Phase 2b "AuTonomy" study for early Alzheimer's disease.
In January 2024, Biogen Inc. announced a strategic reprioritization of its Alzheimer's portfolio, focusing on advancing LEQEMBI (lecanemab-irmb), the first anti-amyloid beta therapy with FDA traditional approval in the US, while accelerating development of new modalities including tau-targeting ASO (BIIB080) and an oral small molecule tau aggregation inhibitor (BIIB113).
Market Research Process:
The Alzheimer's Disease Therapeutics Market research report by DataM Intelligence combines extensive Primary and Secondary research to provide powerful, in-depth insights. It examines key market drivers such as regulatory frameworks, evolving market conditions, competitive dynamics, historical trends, and breakthrough technologies, while spotlighting emerging innovations and potential challenges. This all-inclusive analysis uncovers high-growth opportunities and highlights possible barriers, equipping businesses to tackle market volatility and capture new avenues for success.
Buy Now & Get Instant Access to 360° Market Intelligence:- https://www.datamintelligence.com/buy-now-page?report=alzheimers-disease-therapeutics-market
Market Segments:
By Stage: Early-stage Alzheimer's (Mild), Middle-stage Alzheimer's (Moderate), Late-stage Alzheimer's (Severe)
By Drug Class: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Combination Drugs, Immunotherapy
Global Growth Regions:
⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
Benefits of the Report:
Chapter 1: Opens the report with a comprehensive market overview, highlighting key segments by region, product type, and application. It presents a clear snapshot of market size, growth potential by segment, and both short- and long-term outlook.
Chapter 2: Showcases the most impactful insights, uncovering the emerging trends and disruptive forces shaping the industry's future.
Chapter 3: Delivers an in-depth competitive landscape analysis of the Alzheimer's Disease Therapeutics market, covering revenue shares, strategic moves, and the latest mergers & acquisitions.
Chapter 4: Features detailed profiles of leading players, including their revenue streams, profit margins, product portfolios, and key milestones.
Chapters 5 & 6: Present a granular breakdown of regional and country-level revenue performance, offering a precise view of market size, opportunities, and development prospects worldwide.
Chapter 7: Analyzes market segmentation by product type, revealing the growth potential of each category and spotlighting high-impact.
Chapter 8: Examines application-based market growth, identifying the fastest-expanding sectors and lucrative opportunities for expansion.
Chapter 9: Maps the entire industry supply chain, providing insights into upstream and downstream activities for a complete market perspective.
Chapter 10: Concludes with key findings and actionable takeaways, guiding stakeholders toward strategic decisions and future growth opportunities.
Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/alzheimers-disease-therapeutics-market?kb
Q1: How fast is the Alzheimer's Disease Therapeutics Market growing?
A: The Market is experiencing strong growth and is projected to expand at a CAGR of 7.5% from 2025 to 2032.
Q3: Which Region Leads Alzheimer's Disease Therapeutics Market growth?
A: North America leads the Alzheimer's Disease Therapeutics Market with fastest growth.
Try DataM Subscription Services free for 2 days - Get Started@ https://www.datamintelligence.com/reports-subscription?kb
Make smarter moves with real-time competitor insights, strategic forecasts, and global investment trends-get it all now!
Access your Subscription Dashboard today@ https://www.youtube.com/watch?v=x5oEiqEqTWg
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release United States Alzheimer's Disease Therapeutics Industry Insights: Top Drugs, Pipeline and $46.47B Global Growth here
News-ID: 4191305 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
United States Smart Baby Monitor Market Set to Skyrocket: Key Players - iBaby La …
Smart Baby Monitor Market reached US$ 1.79 Billion in 2024 and is expected to reach US$ 2.99 Billion by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033.
DataM Intelligence has released an in-depth research report on "Smart Baby Monitor Market Size 2025". This report delivers power-packed insights into key growth drivers, market segmentation, regional trends, CAGR forecasts, revenue performance of top players, and emerging opportunities. Gain a…
United States & Japan Probiotic Wellness Drinks Market Boom: Growth Trends, Key …
Probiotic Wellness Drinks Market reached US$ 812.1 million in 2023 and is expected to reach US$ 1,899.9 million by 2031, growing with a CAGR of 12.9% during the forecast period 2024-2031.
DataM Intelligence has released an in-depth research report on "Probiotic Wellness Drinks Market Size 2025". This report delivers power-packed insights into key growth drivers, market segmentation, regional trends, CAGR forecasts, revenue performance of top players, and emerging opportunities. Gain a…
United States Cleaning Robot Industry Opportunities 2025: Leading Companies - So …
US Cleaning Robots market was US$ 2,661.68 million in 2024 and is expected to reach US$ 14,889.06 million in 2032 growing at a CAGR of 24.2% during the forecast period (2025-2032).
DataM Intelligence has released an in-depth research report on "US Cleaning Robot Market Size 2025". This report delivers power-packed insights into key growth drivers, market segmentation, regional trends, CAGR forecasts, revenue performance of top players, and emerging opportunities. Gain a…
United States Potato Protein Market Report: Market Dynamics & Consumer Preferenc …
Global Potato Protein Market reached US$ 1.65 billion in 2023 and is expected to reach US$ 2.56 billion by 2031, growing with a CAGR of 5.64% during the forecast period 2024-2031.
The Potato protein Market receives exhaustive analysis from DataM Intelligence, delivering stakeholders essential market data, emerging industry patterns, and strategic business intelligence. This in-depth research explores the competitive landscape in detail, evaluating market leaders across multiple dimensions including their innovative…
More Releases for Alzheimer
Dementia - Alzheimer Disease Market: A Comprehensive Analysis 2030
Dementia and Alzheimer's disease represent significant challenges within the global healthcare sector. These neurological disorders, characterized by progressive cognitive decline, have seen increasing prevalence due to aging populations worldwide. This growing burden has spurred interest in the Dementia - Alzheimer's disease market, encompassing diagnostic tools, treatments, caregiving solutions, and related healthcare services. This article provides an overview of the market, its scope, current trends, and factors driving its expansion.
Data Bridge…
Alzheimer Disease Treatment Market | Allergan, Amgen, Daiichi Sankyo, Eisai
The global alzheimer disease treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the alzheimer disease treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth…
United States Alzheimer Drugs Market Insights Deep Analysis 2023-2031
Cognate Life Sciences introduces a report on "United States Alzheimer Drugs Market 2023" with Market Insights Reports, Introduces systematic details in terms of market valuation, market size, revenue estimation, and geographical spectrum of the business vertical. The study also talks about crucial pockets of the industry such as products or services offered, downstream fields, end using customers, historic data figures regarding revenue and sales, market context and more. It conjointly…
Global Alzheimer Market, Global Alzheimer Industry, Covid-19 Impact Global Alzhe …
Alzheimer's is a progressive disease that leads to the death of brain cells, resulting in memory loss, behavioral issues, and disruption the thought processes. The Alzheimer disease is considered fatal. Age and heredity are the two main risk factors for developing Alzheimer's disease. Several other preventable risk factors have been associated to the development of this disease, including diet, environment, and overall general health. A combination of risk factors is…
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,…
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports.
Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as…
